Europe Targeted Sequencing Market to Grow with a CAGR of 12.52% through 2030
The growing
advancement in healthcare infrastructure is expected to drive the Europe Targeted
Sequencing Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “Europe Targeted Sequencing Market – By Country, Competition, Forecast & Opportunities, 2030F”,
the Europe Targeted Sequencing Market stood at USD 910.25 million in 2024 and
is anticipated to grow with a CAGR of 12.52% in
the forecast period, 2026-2030. The Europe targeted sequencing market is
experiencing significant growth, driven by the increasing adoption of precision
medicine and personalized healthcare solutions. As the understanding of genetic
information continues to advance, healthcare providers and researchers are
increasingly relying on targeted sequencing to pinpoint specific genetic
mutations that may influence disease development and response to treatment.
This targeted
approach enables more precise and efficient diagnosis and treatment planning,
particularly in fields such as oncology, neurology, and rare genetic disorders.
With advances in next-generation sequencing (NGS) technologies, which allow for
faster and more cost-effective sequencing, Europe is witnessing a rise in the
adoption of these tools across clinical and research settings. As a result,
healthcare providers can deliver tailored therapies that improve patient
outcomes, making targeted sequencing a cornerstone of modern healthcare
practices.
In addition to
precision medicine, the Europe targeted sequencing market is also benefiting
from growing investments in genomics research and biotechnology. As European
countries focus on strengthening their healthcare systems and enhancing
research capabilities, targeted sequencing technologies are becoming integral
to large-scale genomic studies and clinical trials. These technologies support
the discovery of new biomarkers, facilitate drug development, and enable early
disease detection, which is critical in tackling complex diseases like cancer
and genetic disorders. Moreover, the growing focus on improving healthcare
efficiency and reducing treatment costs has fueled the demand for highly
accurate and reliable sequencing technologies. With these ongoing advancements
and a supportive regulatory environment, the European targeted sequencing market
is expected to continue expanding, offering innovative solutions for
personalized healthcare.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Europe Targeted Sequencing Market”
The Europe Targeted
Sequencing Market is segmented into product type, application, end use, and
company.
Based on product
type, the services category is showing the fastest growth in the Europe Targeted
Sequencing market, driven by the increasing adoption
of precision medicine and personalized healthcare solutions. As the
understanding of genetic information continues to advance, healthcare providers
and researchers are increasingly relying on targeted sequencing to pinpoint
specific genetic mutations that may influence disease development and response
to treatment.
As targeted sequencing
becomes more integral to personalized medicine and precision healthcare, the
need for specialized services that ensure high-quality, accurate, and
cost-effective results is also increasing. Service providers in the Europe
targeted sequencing market are expanding their offerings to include data
analysis, interpretation, and storage solutions, which help researchers and
clinicians gain actionable insights from genetic data. Furthermore, the
increasing availability of cloud-based platforms and bioinformatics tools for
data management is accelerating the shift towards outsourced sequencing
services. This trend is expected to continue, making the service category one
of the fastest-growing segments in the European targeted sequencing market.
Based on country, The United
Kingdom is experiencing significant growth in the Targeted Sequencing market,
driven by advancements in healthcare infrastructure, a focus on patient safety,
and a growing emphasis on infection prevention in medical procedures. As a
leading hub for medical research and innovation, the UK is at the forefront of
adopting new technologies and products that enhance the sterility and
efficiency of healthcare systems. The increasing demand for Targeted Sequencing
in hospitals, pharmaceutical manufacturing, and biotechnology sectors is fueled
by the country's commitment to maintaining high-quality healthcare standards
and meeting rigorous regulatory requirements.
Major companies
operating in Europe Targeted Sequencing Market are:
- F.
Hoffmann-La Roche Ltd
- LGC
Limited
- QIAGEN
N.V.
- Illumina
Inc.
- Thermo
Fisher Scientific, Inc..
Download Free Sample Report
Customers can
also request for 10% free customization on this report
"The
growing demand for personalized healthcare solutions is significantly driving
the growth of the targeted sequencing market in Europe. As healthcare providers
and researchers focus on delivering precise treatments based on individual
genetic variations, the need for advanced, accurate, and scalable sequencing
technologies is becoming increasingly critical. The integration of innovative
features such as next-generation sequencing (NGS) platforms, high-throughput
capabilities, and the ability to focus on specific genetic regions has been
essential to meet the diverse needs of clinicians and researchers. As the
market continues to evolve, continuous innovations in sequencing instruments,
bioinformatics tools, and data interpretation methods will play a crucial role
in enabling more accurate and effective diagnostics and treatments, ultimately
transforming healthcare practices across Europe," said Mr. Karan Chechi,
Research Director of TechSci Research, a research-focused management consulting
firm.
“Europe
Targeted Sequencing Market By Product Type (Instruments, Services, Kits/Panels
and Assays, Others), By Application (Cancer, Reproductive Health, Hereditary
Diseases, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases,
Rare Diseases, Other), By End Use (Diagnostic and Clinical Laboratories,
Academic and Research Institutions, Pharmaceutical and Biotech Companies,
Other), By Country, Competition Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of Global Europe Targeted Sequencing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Europe Targeted Sequencing Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com